Ann: PI-88 Phase II Melanoma Clinical Study Resul, page-2

re: Ann: PI-88 Phase II Melanoma Clinical Stu... A long-term drug development project finally comes to its expected inglorious end?

Share price held up (after a few months of quiet gains), so the demise of PI-88 obviously wasn't a surprise.

Progen has some $5 M in the kitty, so does that explain why holders are keeping some kind of faith? That this investable packet will soon find a home now that PGL can stop pretending to have a drug-development pipeline?

So I'll guess this will be the next ex-biotech to morph into a miner.

That's just a guess. Another possibility of course is a capital return to holders, which Progen did a few years back.